GammaTile Therapy is a surgically targeted radiation therapy (STaRT) that provides immediate, dose-intense treatment at completion of resection.
By getting a head STaRT on fighting the tumor, resection plus GammaTile Therapy extends local recurrence-free survival with minimal complications, reduced patient burden, and assured compliance.
Clinical efficacy, immediacy, and efficiency
- Enables immediate treatment at resection with no additional hospital stay
- Integrates into the surgical workflow for procedural ease and speed
- Takes approximately 5 minutes to complete tile placement
- Simplifies care with 100% “built-in” compliance and no special inpatient precautions or contraindications with systemic therapies
How It Works. An Eloquent Solution.
GammaTile™ Therapy targets tumor cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications.
Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment.
Enhanced Local Control and Optimized Efficacy
- 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.
- 88% of the therapeutic dose is delivered within 30 days with more than 95% of dose delivered by 6 weeks.
- A favorable depth-dose profile optimizes local tumor control.
Bioresorbable, conformable collagen tile preserves healthy tissue
- Provides a structural offset of the radiation source from normal brain tissue
- Enforces uniform radiation-source spacing, both within a single tile and between multiple tiles
- Minimizes local hot and cold spots
- Facilitates rapid, accurate placement to deliver a predictable radiation dose
Why Did You Adopt GammaTile Therapy?
GammaTile Therapy Physician Perspective
GT Medical Technologies
The genesis of GT Medical Technologies and GammaTile Therapy
For decades, clinicians have sought better treatment options for patients with brain tumors that would effectively target tumor cells while preserving eloquent tissue.
Driven to overcome the limitations of current treatments and raise the standard of care, a group of brain tumor specialists joined forces to address this critical, unmet need. Together with medical device experts, they developed GammaTile Therapy, Surgically Targeted Radiation Therapy (STaRT) for recurrent intracranial neoplasms.